UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of June 2026
Commission
File Number: 001-42527
Basel
Medical Group Ltd
6
Napier Road,
Unit
#02-10/11 Gleneagles Medical Centre
Singapore
258499
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
BMGL
to Effect Reverse Share Split on June 22, 2026
Basel
Medical Group Ltd (Nasdaq: BMGL) (the “Company”), a medical clinic operator in Singapore, today announced that the Company’s
board of directors has approved the consolidation of the Company’s issued and outstanding shares of the Company on a 1-for-12 ratio
with the marketplace effective date of June 22, 2026.
The
objective of the reverse share split is to enable the Company to re-comply with Nasdaq Marketplace Rule 5550(a)(2), which requires listed
securities to maintain a minimum bid price of $1 per share. According to the law of the British Virgin Islands, the jurisdiction of the
Company’s incorporation, and its memorandum and articles of association, no approval by shareholders and no amendment of the Company’s
articles of association will be required for the reverse share split.
Beginning
with the opening of trading on June 22, 2026, the Company’s ordinary shares which have no par value will trade on the Nasdaq Capital
Market on a split-adjusted basis, under the same symbol “BMGL” but with a new CUSIP number, G0864B111.
As
a result of the reverse share split, every 12 ordinary shares outstanding will automatically combine and convert to one issued and outstanding
ordinary share without any action required on the part of the shareholders. The number of issued and outstanding ordinary shares of the
Company will be correspondingly reduced from 18,785,750 (based on the number of shares outstanding as of June 10, 2026) to approximately
1,565,480, subject to adjustment for rounding. No fractional shares will be issued to any shareholders in connection with the reverse
share split, and each shareholder will be entitled to receive one whole ordinary share of the Company in lieu of the fractional share
that would have resulted from the reverse share split.
EXHIBITS
| 99.1 |
Press release — BMGL to Effect Reverse Share Split on June 22, 2026 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Basel Medical Group Ltd |
| |
|
|
| |
By: |
/s/ Darren
Yen Feng Chhoa |
| |
Name: |
Dr. Darren Yen Feng Chhoa |
| |
Title: |
Chief Executive Officer |
| |
|
|
| Date:
June 10, 2026 |
|
|
Exhibit
99.1
BMGL
to Effect Reverse Share Split on June 22, 2026
SINGAPORE,
June 10, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), a medical clinic operator
in Singapore, today announced that the Company’s board of directors has approved the consolidation of the Company’s issued
and outstanding shares of the Company on a 1-for-12 ratio with the marketplace effective date of June 22, 2026.
The
objective of the reverse share split is to enable the Company to recomply with Nasdaq Marketplace Rule 5550(a)(2), which requires listed
securities to maintain a minimum bid price of $1 per share. According to the law of the British Virgin Islands, the jurisdiction of the
Company’s incorporation, and its memorandum and articles of association, no approval by shareholders and no amendment of the Company’s
articles of association will be required for the reverse share split.
Beginning
with the opening of trading on June 22, 2026, the Company’s ordinary shares which have no par value will trade on the Nasdaq Capital
Market on a split-adjusted basis, under the same symbol “BMGL” but with a new CUSIP number, G0864B111.
As
a result of the reverse share split, every 12 ordinary shares outstanding will automatically combine and convert to one issued and outstanding
ordinary share without any action required on the part of the shareholders. The number of issued and outstanding ordinary shares of the
Company will be correspondingly reduced from 18,785,750 (based on the number of shares outstanding as of June 10, 2026) to approximately
1,565,480, subject to adjustment for rounding. No fractional shares will be issued to any shareholders in connection with the reverse
share split, and each shareholder will be entitled to receive one whole ordinary share of the Company in lieu of the fractional share
that would have resulted from the reverse share split.
About
Basel Medical Group Ltd
Basel
Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well
as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health
and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson
Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong
and lasting relationships with a large base of corporations, particularly those in the construction, marine and oil & gas industries,
which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned
to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations,
rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate
and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team
comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists.
Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based
in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.
For
investor and media inquiries, please contact:
+65
6291 9188
contact@baselmedical.com
